Thyroid Cancer

Bayer and Onyx are evaluating sorafenib in individuals with thyroid cancer.  For a more comprehensive list of Nexavar® (sorafenib) clinical trials, please visit clinicaltrials.gov or call 866-639-2827.

Phase 3 Study of Single Agent Nexavar - DECISION

Currently enrolling
Study Design: Randomized, double-blind, placebo-controlled trial
Patients: Patients with locally advanced or metastatic radioactive iodine-refractory, differentiated thyroid cancer (papillary, follicular and Hurthle cell) who have received no prior systemic therapy
Purpose: To determine the effectiveness of Nexavar in patients with radioactive iodine non-responsive thyroid cancer who have failed to respond to surgical or radiotherapies by assessing the difference in disease progression and overall survival, as well as to evaluate other measures of efficacy and safety
Location: Multiple centers throughout the United States, Europe, Asia and Japan

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204